Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8403131 | 0.93 | KIF11 (0.52) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL765155 | 0.92 | KIF11 (0.49) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL8403148 | 0.92 | KIF11 (0.53) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL763761 | 0.91 | ABCG2 (0.49) | KIF11ABCG2MAPTTP53LMNA | |
| SCHEMBL16299551 | 0.90 | KIF11 (0.53) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL8403168 | 0.89 | KIF11 (0.50) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL11912410 | 0.89 | LMNA (0.46) | KIF11MAPTTP53SMN1; SMN2MEN1 | |
| SCHEMBL763441 | 0.88 | KIF11 (0.52) | KIF11ABCG2MAPTTP53SMN1; SMN2 | |
| SCHEMBL763647 | 0.87 | TP53 (0.47) | KIF11MAPTTP53SMN1; SMN2MEN1 | |
| SCHEMBL16299568 | 0.86 | LMNA (0.48) | KIF11ABCG2MAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | KIF11 2929/4885ABCG2 3060/4885MAPT 4518/4885 |
| US-20090209521-A9 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | KIF11 2929/4885ABCG2 3060/4885MAPT 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.